ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 276,01
-0,04%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ALX Oncology Holdings Inc (ALXO)

  7. ALX Oncology Holdings Inc (ALXO) Actualités

ALXO ALX Oncology Holdings Inc

9,01
-0,27 (-2,91%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ALX Oncology Holdings Inc ALXO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,27 -2,91% 9,01 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,09 8,80 9,3981 9,01 9,28
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/6/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:14EDGAR2Form 144 - Report of proposed sale of securities
02/6/202416:00GLOBEALX Oncology Presents First Evorpacept Combination Data with..
29/5/202415:00GLOBEALX Oncology Announces Participation in the Jefferies Global..
15/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:06EDGAR2Form 144 - Report of proposed sale of securities
09/5/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:00GLOBEALX Oncology Reports First Quarter 2024 Financial Results..
08/5/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:00GLOBEALX Oncology Appoints Allison Dillon as Chief Business..
06/5/202422:02EDGAR2Form 144 - Report of proposed sale of securities
30/4/202415:00GLOBEALX Oncology Announces Initiation of Phase 2..
24/4/202416:00GLOBEALX Oncology Announces Two Evorpacept Abstracts Accepted for..
09/4/202423:30GLOBEALX Oncology Reports Encouraging Clinical Data of Evorpacept..
07/3/202422:05EDGAR2Form 8-K - Current report
07/3/202422:03GLOBEALX Oncology Reports Fourth Quarter and Full Year 2023..
05/3/202422:30GLOBEALX Oncology Announces Two Evorpacept Clinical Abstracts..
17/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:00GLOBEALX Oncology to Present at the 42nd Annual J.P. Morgan..
26/12/202322:01EDGAR2Form 8-K - Current report
13/11/202322:05GLOBEALX Oncology Reports Third Quarter 2023 Financial Results..
13/11/202322:03EDGAR2Form 8-K - Current report
01/11/202321:05GLOBEALX Oncology Announces November Investor Conference..
10/10/202322:05GLOBEALX Oncology Announces Closing of Public Offering, Including..
06/10/202312:06EDGAR2Form 8-K - Current report
06/10/202312:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/10/202314:00GLOBEALX Oncology Announces Pricing of Public Offering
04/10/202323:21EDGAR2Form 8-K - Current report
04/10/202323:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/10/202322:10GLOBEALX Oncology Announces Proposed Public Offering
04/10/202314:00EDGAR2Form 8-K - Current report
03/10/202316:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202312:00GLOBEALX Oncology Reports Positive Interim Phase 2 ASPEN-06..
02/10/202322:05GLOBEALX Oncology to Host Investor Call and Webcast on October 3,..
20/9/202314:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
11/9/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/9/202322:25EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202322:05EDGAR2Form 8-K - Current report
06/9/202314:00GLOBEALX Oncology Realigns Executive Leadership Team
01/9/202322:11EDGAR2Form S-3 - Registration statement under Securities Act of..
31/8/202313:00GLOBEALX Oncology Announces September Investor Conference..
25/8/202322:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:05EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
ALXO
ALX Oncology
BIT
F19471
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés